AI has moved beyond proof-of-concept on the clinical side of pharma, driving rapid discovery of new molecules. But post-market commercialization teams tell a different story: their boards are asking them to use AI to solve the problems caused by multiple rounds of layoffs, mounting pressure to do more with less, and a human capital fabric…
